Brightworth’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Brightworth’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-2,991	Closed	-$262K	–	131
2018 Q1	$262K	Buy	2,991 +2	+0.1%	+$183	0.06%	99
2017 Q4	$254K	Buy	2,989 +62	+2%	+$5.19K	0.06%	99
2017 Q3	$253K	Buy	+2,927	New	+$235K	0.06%	108

Other funds holding XBI

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

AssetMark Inc Concord, California $58.2B AUM 22.78% 1-Year Est. Return

Brightworth's XBI Position: Q2 2018 in Review

Brightworth sold out of State Street SPDR S&P Biotech ETF (XBI) in Q2 2018, closing a stake of 2,991 shares — an estimated $262K sold.

Brightworth first reported a position in XBI in Q3 2017 and held it in 3 quarters. The position peaked at $262K in Q1 2018. 430 funds tracked by Wall St. Rank hold XBI as of Q2 2018.

Brightworth reported no remaining State Street SPDR S&P Biotech ETF position as of Q2 2018 after selling out during the quarter.
Brightworth sold 2,991 State Street SPDR S&P Biotech ETF shares in Q2 2018, an estimated $262K.
Brightworth first reported a position in State Street SPDR S&P Biotech ETF in Q3 2017 and held it in 3 quarters.
Brightworth's State Street SPDR S&P Biotech ETF position peaked at $262K in Q1 2018.
430 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2018.

Based on Brightworth's 13F filing for Q2 2018, filed 3 Aug 2018.